Newsroom | 20513 results

SAN DIEGO--(BUSINESS WIRE)--VedaBio Demonstrates Under-10-Minute Molecular Detection with Target Amplification-Free CRISPR Technology at AMP 2026...

BRISBANE, Calif.--(BUSINESS WIRE)--Durable efficacy and favorable safety profile supports planned 2027 clinical testing in persistent chylomicronemia....

SAN DIEGO--(BUSINESS WIRE)--Seonix Bio, a leader in the development of genetic testing for glaucoma, today announced new research published in Ophthalmology, the American Academy of Ophthalmology’s peer-reviewed journal. The publication reports that the polygenic risk score (PRS) underlying the company’s SightScore™ test can help identify people at substantially different levels of risk for developing glaucoma—and may also help predict disease progression and the likelihood of surgery. Glaucoma...

CARLSBAD, Calif.--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic, “off the shelf”, cell therapies for serious medical conditions, today announced that the Company has acquired NeuroAirmid Therapeutics, Inc. (“NeuroAirmid”) along with certain worldwide rights related to a pluripotent stem cell derived, clinical-stage neural cell therapy program, hNSC-01, which Lineage calls HUNT1, for the treatment of H...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its 2026 fiscal year ended September 30, 2026. The Company is hosting a conference call today, November 12, 2026, at 4:30 p.m. ET to discuss the results. “Arrowhead has fundamentally changed over the past 12 months. Where there was once a company that relied solely on great scientific promise, there is now a company that is beginning to translate promise into real patient outc...

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening diseases, with a strategic focus on inherited cardiovascular disorders, today reported financial results for the third quarter ended September 30, 2026, and provided recent business updates. “With FDA alignment on the pivotal RP-A501 trial in Danon disease, our priority is to complete dosing by mid-2027...

BOSTON & GENÈVE--(BUSINESS WIRE)--Neurosterix, société de biotechnologie clinique qui développe des modulateurs allostériques sélectifs innovants contre les troubles neuropsychiatriques, a annoncé aujourd’hui une levée de fonds de série B d’un montant de 105 millions d'USD. Ce tour de table a été conduit par RTW Investments, avec la participation de nouveaux investisseurs dont Janus Henderson Investors, GV, Ikarian Capital, Affinity Asset Advisors et Dellora Investments, qui rejoignent les inve...

BOSTON & GENF--(BUSINESS WIRE)--Neurosterix, ein Biotechnologieunternehmen für das klinische Stadium, das neuartige, selektive allosterische Modulatoren für neuropsychiatrische Erkrankungen entwickelt, gab heute den Abschluss einer Serie-B-Finanzierungsrunde in Höhe von $105 Millionen bekannt. Die Runde wurde von RTW Investments angeführt, unter Beteiligung der neuen Investoren Janus Henderson Investors, GV, Ikarian Capital, Affinity Asset Advisors und Dellora Investments sowie der bestehenden...

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced new long-term data for DAWNZERA® (donidalorsen), the first and only RNA-targeted medicine for hereditary angioedema (HAE), to be presented at the 2026 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting in Phoenix, Arizona. Multiple presentations will demonstrate the long-term efficacy and safety of DAWNZERA in the OASISplus open-label extension (OLE) and switch cohort...

SEATTLE--(BUSINESS WIRE)--Volta today announced the AXELIOS 1 Library Prep App, (SBX-D chemistry) on the Callisto™ Sample Prep System, in collaboration with Roche Diagnostics....